Cell treatment on track for Phase II stroke trial

04/27/2012 | ProactiveInvestors.co.uk (U.K.)

The stem cell therapy ReN001 is being used in early clinical trials to treat 12 patients disabled by stroke, and an application is on track for a midstage study in 2013. The therapy is based on stem cell developer ReNeuron's lead neural stem cell line. ReNeuron is also developing treatments for peripheral arterial disease and retina diseases.

View Full Article in:

ProactiveInvestors.co.uk (U.K.)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
BCBS-Louisiana
Baton Rouge, LA
Director, Global Integrity and Compliance, Pharmaceuticals
Alcon
Fort Worth, TX